PDL BioPharma

                   

Learn about the World Biotechnology Market Brief (Business Wire)

yahoo.com
15 hrs ago 17 related
        

Tuesday November 18, 8:27 am ET NEW YORK--(BUSINESS WIRE)--Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue. Market (2003):...

add comment
                   

Research and Markets: Understand Immunogenicity to Biologics and Develop the Relevant Safety...

tmcnet.com
13-Nov-2008
        

Dublin - Research and Markets (http://www.researchandmarkets.com/research/R896f24/immunogenicity_to) has announced the addition of the "Immunogenicity to Biologics" report to their offering. Failure to predict and minimise...

add comment
                   

Ophthotech Treats First Patient In A Phase I Trial Of Monoclonal Antibody, Volociximab, For...

bioresearchonline.com
11-Nov-2008 2 related
        

Ophthotech Corp. announced recently the treatment of its first patient with Volociximab, a monoclonal antibody targeting alpha5beta1 integrin, in a Phase I trial for the treatment of wet age-related macular degeneration (AMD).

add comment
                   

Anesiva kills sole marketed drug, cuts staff, reports other problems

drugpolicycentral.com
10-Nov-2008 11 related
        

It did, however, work at four to 48 hours after surgery and reduced opioid use over the four- to 32-hour period, the company said. ... (Mon Nov 10 15:04:26 2008 PST)[$drug_related(100%), $drugwar_propaganda(60%),...

add comment
pharmiweb.co.uk: Genetic Engineering pharmiweb.co.uk

PDL BioPharma Appoints John P. McLaughlin to Become President and CEO Upon Completion of Spin-Off...

pharmiweb.co.uk
08-Nov-2008 14 related
        

PDL BioPharma, Inc. (PDL) announced that its board of directors has appointed John P. McLaughlin to become president and chief executive officer (CEO) following the company's planned spin-off of its biotechnology assets....

add comment

PDL BioPharma swings to profit in Q3 - Quick Facts

pharmiweb.co.uk
06-Nov-2008 3 related
        

11/6/2008 4:32 PM ET (RTTNews) - PDL BioPharma Inc. (PDLI: News ) posted third quarter net income of $55.6 million or $0.38 per share, compared to a net loss of $5.7 million or $0.05 per share in the previous year quarter. On...

add comment
                   

Complement factor aptamer. Combination with anti-VEGF agent. “… anti-C5 aptamer blockade...

sujanani.com
29-Oct-2008
        

Ophthotech Corp has reported “… the enrollment of its first patient in a complement inhibition trial for the treatment of age-related macular degeneration (AMD). This Phase I trial will assess the safety and tolerability of...

add comment

Multiple Myeloma Research Consortium Initiates Phase 1B Study Of Elotuzumab Monoclonal Antibody...

medicalnewstoday.com
27-Oct-2008
        

The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a three-drug combination study of elotuzumab (also known as HuLuc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously,...

add comment
                   

Enzon Shareholders Steal the Show (at Motley Fool)

yahoo.com
26-Oct-2008
        

On Tuesday, Enzon Pharmaceuticals (Nasdaq: ENZN) wanted to trumpet its first-ever data presentations at a major medical conference. Too bad an activist investor chose that same day to prod Enzon to consider more strategic...

add comment
                   

Bristol-Myers Squibb Continues Excellent Financial Performance Led By Double-Digit Global Net...

pharmiweb.co.uk
25-Oct-2008 1 related
        

NEW YORK-- Bristol-Myers Squibb Company (NYSE:BMY): Reports Broad-Based Net Sales Growth of 14% from Continuing Operations Records Growth in GAAP Diluted EPS of $1.29 Compared to $0.43 in 2007; Includes After-Tax Gain of $0.99...

add comment